Chakos M H, Mayerhoff D I, Loebel A D, Alvir J M, Lieberman J A
Psychiatry Research Department, Hillside Hospital, Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, NY 11004.
Psychopharmacol Bull. 1992;28(1):81-6.
The incidence and correlates of extrapyramidal symptoms (EPS) in neuroleptic treatment of schizophrenic patients have been reported for chronic patients but not for first-episode patients. We examined the incidence and correlates of extrapyramidal symptoms in a cohort of 70 treatment-naive patients who received fluphenazine at 20-40 mg/day for the first 10 weeks of treatment. Thirty-four percent of our sample developed parkinsonism, 18 percent developed akathisia, and 36 percent developed dystonia. Acute EPS were associated with greater baseline psychopathology. Acute EPS were also associated with better treatment outcome in terms of time to and level of remission. These findings suggest that the EPS response of neuroleptic-naive patients may differ from that of chronically ill patients and that acute EPS status may be an indicator of pharmacologic responsivity in this group.
已有报道称,在精神分裂症患者的抗精神病药物治疗中,锥体外系症状(EPS)的发生率及其相关因素,但这些报道均针对慢性患者,而非首发患者。我们对70例未接受过治疗的患者进行了研究,这些患者在治疗的前10周接受了每天20 - 40毫克氟奋乃静的治疗,我们考察了锥体外系症状的发生率及其相关因素。我们样本中的34%出现了帕金森症,18%出现了静坐不能,36%出现了肌张力障碍。急性锥体外系症状与更高的基线精神病理学症状相关。就缓解时间和缓解程度而言,急性锥体外系症状也与更好的治疗效果相关。这些发现表明,未使用过抗精神病药物的患者的锥体外系症状反应可能与慢性病患者不同,并且急性锥体外系症状状态可能是该组药物反应性的一个指标。